【Product for Licensing】T-cell engager (TCE), bispecific, trispecific, and multispecific products are available

If you are interested in similar assets, please contact DrugTimes BD Team at BD@drugtimes.cn asap. Many thanks!~

T-cell engagers (TCEs) represent an innovative approach in immunotherapy, with applications and values highlighted in the following areas:

Applications in Cancer Treatment

TCEs effectively target and kill cancer cells by simultaneously binding to tumor-associated antigens (TAAs) and CD3 on T-cells. In hematological malignancies, TCE drugs targeting antigens such as CD19, CD20, and BCMA have been commercialized and shown significant efficacy. Additionally, TCE drugs are expanding into the fields of solid tumors and autoimmune diseases. For instance, Amgen’s Tarlatamab (CD3/DLL3) has been marketed in the United States for the treatment of extensive-stage small cell lung cancer (ES-SCLC).

Innovations in Immunotherapy

TCEs offer a novel immunotherapy method that induces a more potent and sustained immune response by directly recruiting and activating T-cells. Globally, there are over 400 TCE drug pipelines under research, with the number increasing annually, and approximately 50% have entered clinical stages.

Development of Multispecific TCEs

Beyond bispecific TCEs, trispecific and multispecific TCE products are also in development, enhancing therapeutic efficacy and selectivity.

Licensing Agreements for TCEs

Recently, there has been a flurry of licensing activities in the TCE field, demonstrating the interest of major pharmaceutical companies in the next generation of TCE products and reflecting the potential and market value of TCEs in cancer treatment:

  • Candid Therapeutic’s Deals: On December 16, Candid Therapeutic announced three R&D collaboration deals concerning TCEs, involving Harbour Biomed’s wholly-owned subsidiary Nona Biosciences, Epimab Biotherapeutics, and Ab Studio, with a total potential transaction value exceeding $1.32 billion.
  • Curon Biopharma and Merck’s Deal: Tongrun Biotech reached a CD3/CD19 bispecific TCE deal with Merck, with a total transaction value of $1.3 billion, including an upfront payment of $700 million and up to $600 million in milestone payments.
  • Chimagen Bio and GSK’s Deal: Enmu Bio licensed its dual-targeting CD19 and CD20 T-cell engager (TCE) CMG1A46 to GSK, with an upfront payment of $300 million and a potential total deal value of $850 million.
  • Vir Biotechnology and Sanofi’s Deal: Vir Biotechnology entered into a global exclusive licensing agreement with Sanofi, granting Vir global exclusive rights to three clinical-stage TCEs targeting different cancer antigens, currently in Phase I clinical studies or preparing to begin trials.
  • AbbVie and EvolveImmune Therapeutics’ Deal: AbbVie collaborated with EvolveImmune Therapeutics to co-develop oncology drugs using its proprietary TCE platform, with a transaction value of $1.465 billion.

These licensing agreements not only showcase the vibrancy of the TCE field but also reflect the significance and market potential of TCEs in cancer treatment. With the development and commercialization of more TCE products, this field is expected to continue growing.

If you are interested in similar assets, please contact DrugTimes BD Team at BD@drugtimes.cn asap.

Many thanks!~

发布者:DrugTimes001,转载请首先联系contact@drugtimes.cn获得授权

(0)
打赏 为好文打赏 支持药时代 共创新未来! 为好文打赏 支持药时代 共创新未来!
上一篇 2024年12月30日 16:02
下一篇 2024年12月31日 19:26

相关推荐

公众号
公众号
分享本页
返回顶部